Fujirebio
Top Five Articles on 360Dx Last Week: Digital Pathology Adoption; FDA Reclassify Hep B Tests; More
Last week, readers were most interested in a story about whether digital pathology is approaching a breakout moment in its adoption curve.
Fujirebio Files Blood-Based Alzheimer's Test With FDA
The test measures levels of p-tau 217 and β-Amyloid 1-42 in human plasma to identify patients with the amyloid brain pathology characteristic of Alzheimer's disease.
Davos Alzheimer's Collaborative Creates Initiative to Improve Alzheimer's Diagnosis
Under the program, blood biomarkers and confirmatory diagnostic testing will be used to increase diagnosis of Alzheimer’s disease and related dementias.
Two studies, led by researchers at Oxford and University College London, aim to explore whether blood-based markers can speed up diagnoses and improve outcomes.
Top Five Articles on 360Dx Last Week: FDA 510(k) Clearances; QuidelOrtho Update; More
Last week, readers were most interested in a story about FDA clearances granted in February.